Ascentage Pharma Group International has announced its global innovation strategy for 2026, focusing on expanding its presence in hematologic malignancies and solid tumors. The company plans to accelerate global clinical development and product commercialization, with particular emphasis on advancing its pipeline of innovative therapies. Key future activities include progressing multiple global registrational Phase III trials and expanding the use of its proprietary protein degradation technology. The strategy also involves the clinical development of APG-3288, a next-generation BTK degrader, following investigational new drug clearance from the U.S. FDA. Ascentage Pharma aims to address unmet clinical needs worldwide and strengthen its global portfolio of commercialized products and late-stage clinical programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9626156) on January 15, 2026, and is solely responsible for the information contained therein.